These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 22935483)

  • 1. Mechanisms of anemia in CKD.
    Babitt JL; Lin HY
    J Am Soc Nephrol; 2012 Oct; 23(10):1631-4. PubMed ID: 22935483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.
    Babitt JL; Lin HY
    Am J Kidney Dis; 2010 Apr; 55(4):726-41. PubMed ID: 20189278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia in chronic kidney disease: new advances.
    Patel TV; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):347-57. PubMed ID: 20630409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepcidin in chronic kidney disease anemia.
    Santos-Silva A; Ribeiro S; Reis F; Belo L
    Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of anemia in chronic kidney diseases: A review.
    Zadrazil J; Horak P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):197-202. PubMed ID: 24401900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease.
    Panwar B; Gutiérrez OM
    Semin Nephrol; 2016 Jul; 36(4):252-61. PubMed ID: 27475656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology.
    Cases A; Egocheaga MI; Tranche S; Pallarés V; Ojeda R; Górriz JL; Portolés JM
    Nefrologia (Engl Ed); 2018; 38(1):8-12. PubMed ID: 29128260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
    Landau D; London L; Bandach I; Segev Y
    PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepcidin is a potential regulator of iron status in chronic kidney disease.
    Tsuchiya K; Nitta K
    Ther Apher Dial; 2013 Feb; 17(1):1-8. PubMed ID: 23379486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron deficiency in ND-CKD: from diagnosis to treatment].
    Liberti ME; Garofalo C; Sagliocca A; Borrelli S; Conte G; De Nicola L; Minutolo R
    G Ital Nefrol; 2017 Sep; 34(5):50-61. PubMed ID: 28963827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease.
    Kim IY; Kim JH; Kim MJ; Lee DW; Hwang CG; Han M; Rhee H; Song SH; Seong EY; Lee SB
    Int Urol Nephrol; 2018 Dec; 50(12):2255-2260. PubMed ID: 30136086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease.
    Nakanishi T; Kimura T; Kuragano T
    Contrib Nephrol; 2019; 198():124-134. PubMed ID: 30991414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
    Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
    Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulating iron-erythropoiesis regulation: transferrin receptor 2 as potential target for treating anemia in CKD.
    Koury MJ; Haase VH
    Kidney Int; 2023 Jul; 104(1):25-28. PubMed ID: 37349056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of iron status in chronic kidney disease.
    Hayes W
    Pediatr Nephrol; 2019 Apr; 34(4):605-613. PubMed ID: 29666917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review.
    Hamza E; Metzinger L; Metzinger-Le Meuth V
    Cells; 2020 Sep; 9(9):. PubMed ID: 32899941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOVEL IRON BIOMARKERS IN CHRONIC KIDNEY DISEASE.
    Zapora-Kurel A; Malyszko J
    Wiad Lek; 2021; 74(12):3230-3233. PubMed ID: 35058395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia in children with chronic kidney disease.
    Greenbaum LA
    Adv Chronic Kidney Dis; 2005 Oct; 12(4):385-96. PubMed ID: 16198278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.